The discovery of PD-L1 receptors sparked off a great interest in immunotherapeutics for the management of locally advanced NSCLC. The beneficence of immunotherapeutics for overall survival in locally advanced NSCLC is proven by several clinical trials. Still, no data exist for the relationship between RT response and PD-L1 receptor positivity in the literature. In this regard, we aimed to investigate the predictor value of PD-L1 receptors for RT response. Eighty patients diagnosed with locally advanced NSCLC have been selected among the patients that PD-L1 status did work in the Gazi University pathology laboratory. The relationship between PD-L1 and PFS, OS, MFS, RT response, RT doses were evaluated with Kaplan Meier and Cox regression analysis. Chi-square and T-tests were used for descriptive statistics. The median follow-up was 16.1 months. The mean age was 61.1 years old. PD-L1 positivity was detected in 34 patients. One year and 2-year OS and PFS ratios were found as 87%, 54%, and 65%, 30%, respectively. Median OS and PFS were 26.8 and 15.1 months, respectively. There is no statistically significant difference between PD-L1 receptor status and OS and PFS (p=0.736, p=0.372 respectively). In PD-L1 positive subgroup analysis for OS, doses higher than 60 Gy (n=28, mean dose 64.6±1.53) were found superior to the 60 Gy dose (n=6) (p=0.034). Median MFS was 33 months. PD-L1 status did not seem a predictor for RT response. However, despite the low number of patients in the 60 Gy group, it is showed dose-escalation could improve survival in PD-L1-positive locally advanced NSCLC. We are aware of our data is too weak to support that hypothesis. However, this may lead to further clinical trials for dose escalation in locally advanced NSCLC, and in the era of tailored therapy, this knowledge may provide valuable information for selecting the proper RT dose for patients.